Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Drug to prevent organ rejection after kidney transplant tops standard treatment in trial

Key Takeaway: A new drug developed to prevent organ rejection after kidney transplants has demonstrated superior efficacy compared to standard treatments in recent clinical trials. This advancement could significantly enhance patient outcomes and transform post-transplant care. The results indicate a promising future for patients receiving kidney transplants.
Price reaction · baseline $3.87 (2026-06-25T16:10:00.000Z) · hit during market hours · 2 other ELDN headline(s) in the window, move may be shared
day 0 close · peak
-5.7%
day 1
-2.3%
day 3
+1.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • The new drug shows promise in preventing organ rejection.
  • It outperforms standard treatments in clinical trials.
  • Potential to improve patient outcomes significantly.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is the new drug's purpose?

The new drug aims to prevent organ rejection after kidney transplants.

How does the new drug compare to standard treatments?

It has shown superior efficacy in clinical trials compared to standard treatments.

What are the potential benefits of this drug?

The drug could significantly improve patient outcomes post-transplant.

Last updated: Jun 25, 2026